NCT03790605

Brief Summary

The study will follow a parallel arm, randomised, double blinded, placebo controlled design. There will be two groups Group 1 = receiving 1% curcumin chips after routine scaling and root planing (n=20) Group 2 = receiving placebo chips after routine scaling and root planing (n=20) Clinical parameters: ( Baseline, 4 weeks, 12 weeks) Probing pocket depth, clinical attachment level, gingival index, plaque index Cytokine parameter ( Baseline, 4 weeks) Interleukin 1 beta in GCF Statistical analysis Repeated measures of ANOVA Paired t-tests

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Sep 2019

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 19, 2018

Completed
12 days until next milestone

First Posted

Study publicly available on registry

December 31, 2018

Completed
8 months until next milestone

Study Start

First participant enrolled

September 4, 2019

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

December 13, 2019

Status Verified

December 1, 2019

Enrollment Period

12 months

First QC Date

December 19, 2018

Last Update Submit

December 12, 2019

Conditions

Keywords

periodontitis, 1% curcumin chips, host modulation therapy, anti inflammatory effect, interleukin 1 beta

Outcome Measures

Primary Outcomes (1)

  • Cytokine parameter

    Intragroup comparison within each group (1-curcumin group and 2- placebo group) and intergroup comparison between the two groups of levels of interleukin 1 beta in the gingival crevicular fluid quantified by ELISA in picogram per milliliter

    Change from Baseline to 4 weeks

Secondary Outcomes (4)

  • Probing pocket depth

    Changes from Baseline to 4 weeks and 12 weeks

  • Clinical attachment level

    Changes from Baseline to 4 weeks and 12 weeks

  • Gingival Bleeding Index by Loe and Silness in 1963

    Changes from Baseline to 4 weeks and 12 weeks

  • Plaque index by Silness and Loe in 1964

    Baseline from. 4 weeks, 12 weeks

Study Arms (2)

1% curcumin chip

EXPERIMENTAL

Following routine full mouth scaling and root planing within 48 hours, a single chip of 1% curcumin will be placed locally within a single isolated periodontal pocket(the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip(second placement)

Drug: 1 % curcumin chipProcedure: Scaling and root planing

Placebo chip

PLACEBO COMPARATOR

Following routine full mouth scaling and root planing within 48 hours, a single placebo chip will be placed locally within a single isolated periodontal pocket (the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip (second placement)

Other: Placebo chipProcedure: Scaling and root planing

Interventions

CURCUMIN CHIP: 4x5x0.5mm chip of 1% curcumin in biodegradable hydroxy propyl methyl cellulose vehicle

1% curcumin chip

PLACEBO CHIP: 4x5x0.5mm chip (identical to test chip except for the active therapeutic ingredient) in biodegradable hydroxy propyl methyl cellulose vehicle

Placebo chip

Routine full mouth scaling and root planing within 48 hours will be performed at baseline prior to local placement of the chips

1% curcumin chipPlacebo chip

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Systemically healthy individuals
  • Presence of a minimum of 20 teeth in the oral cavity
  • Localised periodontal pockets with probing depths greater than 4mm i.e., Periodontitis in its stages 2 and 3, as described by the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions, and published by the American Academy of Periodontology (AAP)

You may not qualify if:

  • Known allergy to curcumin and/ or hydroxyl propyl methyl cellulose
  • Systemic diseases and/or Inflammatory conditions, Obesity
  • Former or current tobacco users
  • Chronic consumption of alcohol
  • Use of anti-inflammatory drugs and antibiotics over the past 3 months
  • Periodontal therapy in any form, surgical or non surgical in the past 6 months
  • Pregnant and lactating mothers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

K L E society's Dental College

Bangalore, Karnataka, 560022, India

RECRUITING

MeSH Terms

Conditions

Periodontitis

Interventions

Tooth ExfoliationRoot Planing

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

Dental Physiological PhenomenaDigestive System and Oral Physiological PhenomenaDental ScalingDental ProphylaxisPeriodonticsDentistrySubgingival CurettagePreventive Dentistry

Central Study Contacts

Riya A Daniel, BDS, PG student

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
The study design follows a double blinded design where the participant and the outcome assessor are unaware of the intervention to the subject
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Total subjects = 40 INCLUSION CRITERION 1. Systemically healthy individuals both males and females of 20-60 years 2. Presence of a minimum of 20 teeth in the oral cavity 3. Localised periodontal pockets with probing depths greater than 4mm i.e., Periodontitis in its stages 2 and 3, as described by the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions, and published by the American Academy of Periodontology (AAP) EXCLUSION CRITERION 1 Known allergy to curcumin and/ or hydroxyl propyl methyl cellulose 2 Systemic diseases and/or Inflammatory conditions, Obesity 3 Former or current tobacco users 4 Chronic consumption of alcohol 5 Use of anti-inflammatory drugs and antibiotics over the past 3 months 6 Periodontal therapy in any form, surgical or non surgical in the past 6 months 7 Pregnant and lactating mothers
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Post graduate student, Principal Investigator, Department of Periodontics, KLE Society's Institute of Dental Sciences, Bangalore

Study Record Dates

First Submitted

December 19, 2018

First Posted

December 31, 2018

Study Start

September 4, 2019

Primary Completion

September 1, 2020

Study Completion

December 1, 2020

Last Updated

December 13, 2019

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will not share

For the purpose of confidentiality, as will be promised to the participants while signing the informed consent, all individual records except that of the parameters assessed during the study and the photographs taken will remain unshared to the public or fellow researchers

Locations